Zobrazeno 91 - 100
of 1 913
pro vyhledávání: ''
Autor:
Yuanquan Yang, Balazs Halmos, Janaki Sharma, Roman Perez-Soler, Christopher Su, Haiying Cheng, Kenny Ye, Lei Deng, H. Dean Hosgood
Publikováno v:
Clin Lung Cancer
Little is known about the difference between black and non-black patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), particularly regarding survival. We thus characterized the EGFR expression profile, cli
Publikováno v:
Future Oncology. 16:439-449
Aim: To investigate the predictive potential of post-treatment neutrophil-to-lymphocyte ratio (NLR) and changes in this ratio (ΔNLR) for stage III non-small-cell lung cancer (NSCLC) patients who received conventionally fractionated radiotherapy (CFR
Autor:
Shan Xing, Lin Chen, Wanli Liu, Sheng Qin, Jianhua Xu, Xianzhang Huang, Yonghe Chen, Kai Lan, Wan Wang, Rongliang Liang, Caiying Bai, Haibiao Lin, Fudong Luo, Dan Liu
Publikováno v:
Cancer Science
The signaling of interleukin (IL)‐23 and its receptor (IL‐23R) play a crucial role in the development of cancers. However, the clinical significance of human serum soluble IL‐23R (sIL‐23R) and its relationship with IL‐23 are still not explo
Autor:
Kazuya Shinmura, Yuji Iwashita, Masayuki Tanahashi, Kazuhito Funai, Haruhiko Sugimura, Takafumi Suda, Katsuhiro Yoshimura, Naoki Inui, Hiroshi Niwa, Masato Karayama, Hidetaka Yamada, Akikazu Kawase, Yusuke Inoue, Hiroshi Ogawa, Kazuo Tsuchiya
Publikováno v:
Lung Cancer. 141:21-31
Alterations in the MET gene, such as mutations and high-level amplification, are important drivers of non-small cell lung cancer (NSCLC). The efficacy of immune checkpoint inhibitors (ICIs) in lung cancer with MET abnormalities is unclear. We evaluat
Autor:
Takashi Seto, Noboru Yamamoto, Takeharu Yamanaka, Yuichiro Ohe, Makoto Nishio, Tatsuya Yoshida, Toyoaki Hida, Akira Ono, Takayasu Kurata, Kentaro Sakamaki, Hiroaki Okamoto, Miyako Satouchi, Seiji Niho, Koichi Goto, Tetsuo Akimoto
Publikováno v:
Lung Cancer. 141:64-71
Objectives SPECTRA is a multicenter, randomized phase II study of chemotherapy with cisplatin (CDDP) plus S-1 versus CDDP plus pemetrexed (PEM) in combination with thoracic radiotherapy (TRT) for locally advanced non-squamous non-small cell lung canc
Autor:
Masato Watanabe, Masafumi Kawamura, Hiroshi Uozaki, Shigeki Morita, Masanori Yasuda, Shiori Watabe, Satoe Numakura, Noriyuki Matsutani, Daisuke Komura, Arisa Kumagai-Togashi, Yoshinao Kikuchi
Publikováno v:
Cancer Medicine, Vol 9, Iss 8, Pp 2879-2890 (2020)
Cancer Medicine
Cancer Medicine
Background Pre‐resection pleural lavage cytology is useful to predict tumor recurrence and the prognosis of lung cancer patients. Recently, extracellular vesicles (EVs) isolated from effusion specimens have come under the spotlight, and several stu
Autor:
Hui Zhang, Xiao Yunpeng, Jian Zhang, Hua-Xin Liao, Jun Jiang, Qian-Ting Wang, Li Junqi, You-Wen He, Xiaohui Yuan, Shiyou Li, Zhe Li, Yu-Ying Fan, Sheng-Nan Sun, Ming Zeng, Ru-Jin Han, Bin-Bin Zhao, Ying Nie, Tao Lin
Publikováno v:
Cancer Immunology, Immunotherapy. 69:1375-1387
Tumor-associated antigens (TAAs) have been tested in various clinical trials in cancer treatment but the patterns of specific T cell response to personalized TAA immunization remains to be fully understood. We report antigen-specific T cell responses
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 146:1235-1243
This prospective study evaluated whether peripheral blood biomarkers and metabolic parameters on F-18 fludeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) could be associated with clinical outcome in non-small cell lung
Autor:
Jang Ho Cho, Eun Joo Kang, Se-Hoon Lee, Jin Seok Ahn, Keon Uk Park, Myung-Ju Ahn, Sung Hee Lim, Ki Hwan Kim, Yoonhee Choi, Keunchil Park, Myung Hee Lee, Jong Mu Sun, Ho Jung An, Mi Sun Ahn
Publikováno v:
Journal of Clinical Oncology. 38:488-495
PURPOSE Approximately 10% of patients with epidermal growth factor receptor (EGFR) mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here, we report the efficacy and safety of osimertinib in patients with NSCLC harbo
Autor:
Yusuke Shinchi, Daiki Yoshii, Koei Ikeda, Makoto Suzuki, Takuro Sakagami, Yoshihiro Komohara, Yusuke Tomita, Eri Matsubara, Kensaku Sato, Yukio Fujiwara, Koji Ohnishi, Remi Mito
Publikováno v:
Pathology International. 70:287-294
Tumor-associated calcium signal transducer 2 (TROP2) is a cell-surface glycoprotein involved in the high malignant potential of several cancers. Antibody-drug conjugates that target TROP2 represent a promising approach for the treatment of TROP2-expr